Onconetix Shareholders Approve Flexible Reverse Stock Split Authorization

Onconetix ( (ONCO) ) just unveiled an update.

On April 30, 2026, Onconetix, Inc. held a special meeting of stockholders to vote on an amendment to its certificate of incorporation that would authorize the board to implement one or more reverse stock splits in a range of 1-for-2 to 1-for-10, provided that all such actions do not exceed an aggregate 1-for-100 ratio. Shareholders also considered a proposal to allow adjournment of the meeting if additional time was needed to secure votes for the reverse split authorization.

Based on 3,464,686 shares of common stock outstanding as of the March 13, 2026 record date, both proposals were approved, with the reverse stock split measure receiving 1,301,918 votes in favor and the adjournment proposal receiving 1,332,088 votes in favor. The approvals give Onconetix’s board flexibility to manage the company’s share structure over the coming year, which may affect share liquidity, trading price dynamics, and the interests of existing stockholders.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetix, Inc. operates in the healthcare and biotechnology sector, focusing on oncology-related products and services. The company’s common stock is publicly traded, and its capital structure and share count are key considerations for its shareholders and corporate governance decisions.

Average Trading Volume: 7,773,091

Technical Sentiment Signal: Sell

Current Market Cap: $440K

For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.